The International Workshop on Molecular Aspects of Myeloid Stem Cell Development and Leukemia

Since 1990, the biennial International Workshop on Molecular Aspects of Myeloid Stem Cell Development and Leukemia has been the premier global meeting which spans fundamental stem cell biology and function, myeloid cell differentiation, marrow failure syndromes and myeloid cell malignancies. At the 2026 installment of the meeting (“MYELOID2026”), scientists with expertise in normal and abnormal hematopoiesis and clinicians who treat patients with myeloid leukemias, malignancies, and pre-leukemic disorders and also have active research programs in these diseases will achieve a better understanding of critical steps/factors that regulate hematopoiesis, their impact on transformation and disease resistance, and their potential relevance in clinical settings. MYELOID2026 will stimulate the community with collaborations on active projects, educate trainees, and “cross pollinate” critical and influential sectors of multiple myeloid biology fields. Moreover, the meeting size, meeting program, and ratio of trainees to faculty at the MYELOID meetings, provide trainee attendees ample opportunities for networking and faculty engagement for project discussions. We expect several landmark studies for the respective fields of normal hematopoiesis, stem cell biology, and myeloid malignancies to result from presentations by attendees. MYELOID2026 will bring together world renowned scientists, clinicians, and trainees to improve our understanding of hematopoietic development and differentiation, stem cells, and the evolution of myeloid malignancies. Project Number: 1R13CA313846-01 | Fiscal Year: 2026 | NIH Institute/Center: National Cancer Institute (NCI) | Principal Investigator: H. GRIMES (+1 co-PI) | Institution: CINCINNATI CHILDRENS HOSP MED CTR, CINCINNATI, OH | Award Amount: $20,000 | Activity Code: R13 | Study Section: Special Emphasis Panel[ZRG1 SCIL-T (80)] View on NIH RePORTER: https://reporter.nih.gov/project-details/11371884